Abstract
Sustained high level of efficacy and favorable safety of ixekizumab in psoriasis: 4 years of follow-up from UNCOVER-3
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have